Daebongls.Co.,Ltd. (078140) Fair Value & Analysis
Healthcare · KR · Market cap 86.4B KRW
Fair value as of: Jul 20, 2026
From 14 valuation models · updated 21 days ago
Share price +6.1% over the past month.
Below-average quality, screening 68% undervalued on our models.
What matters now
- The large discount to fair value meets weak quality (44/100). That raises the risk this is a value trap rather than a bargain.
- The price is below even our cautious bear case (10,357 KRW). The market is more pessimistic than our downside scenario.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 20, 2026.
How to read this chart
60‑month range 6,803 KRW – 23,561 KRW · fair‑value band 10,357 KRW – 17,261 KRW · the 8,220 KRW price screens below the 13,809 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 20, 2026.
Analysis
Daebongls.Co.,Ltd. (078140) currently trades at 8,220 KRW, while our model-based Fair Value estimate is 13,809 KRW, implying the stock looks roughly 68.0% undervalued today. The Quality Score stands at 44/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium), always confirm before acting.
Over the trailing twelve months, Daebongls.Co.,Ltd. generated revenue of 92.0B KRW at a net margin of 5.2%. Revenue grew 10.2% year over year. Net debt stands at 63.3B KRW. Fundamentals as of Jul 20, 2026
Our scenario range runs from 10,357 KRW (bear case) to 17,261 KRW (bull case); at 8,220 KRW, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 47% below its 52-week high and 4% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -20% fair-value upside, at 68%, 078140 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 14 models by family
Widest divergence: Growth Earnings (14,248 KRW) versus Multiples (5,327 KRW). Highest evidence: Residual Income (76).
Notify me when 078140 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 20, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 43 · Market factors (momentum, volatility) 22
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Daebongls.Co.,Ltd. engages in the research, development, and production of cosmetics, pharmaceutical raw materials, food and feed products in South Korea and internationally.
Full company description
Daebongls.Co.,Ltd. engages in the research, development, and production of cosmetics, pharmaceutical raw materials, food and feed products in South Korea and internationally. The company's Cosmetic Ingredients division offers special cosmetic ingredients comprising fresh green tea, black ginseng water, jeju hatban extract, wormwood extract, jeju camellia oil, jeju dang oil extract, jeju basalt powder, jeju active complex, and ginseng flower extract; and natural and synthesis cosmetics like moisturizing, skin protection, whitening, anti- aging, skin care, and hair care products. The company's Pharmaceutical Raw Material division develops the API of respiratory, hypertension, digestive-system treatments, and medicines and supply excipients to domestic companies as an agent for global companies. The company's Food & Feed division manufactures and distributes functional additives, protein products, amino acids, and vitamins. Daebongls.Co.,Ltd. was founded in 1986 and is headquartered in Incheon, South Korea.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Daebongls.Co.,Ltd. reported revenue of 102B KRW in FY2025 versus 83.0B KRW in FY2021, a compound +5.3%/yr. Reported net income was 10.1B KRW in FY2025, compounding +10.3%/yr from FY2021.
Watch 078140: get an alert when its fair value changes →
Peer Group
Pharmaceuticals · 25 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Pharmaceuticals stocks, each showing price versus our Fair Value estimate (as of Jul 20, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| GlaxoSmithKline Pharmaceuticals Limited 500660 | ₹2,653 | ₹1,471 | -45% |
| Caregen Co 214370 | 62,700 KRW | 7,277 KRW | -88% |
| ST Pharm Co 237690 | 123,600 KRW | 50,110 KRW | -59% |
| Oscotec Inc 039200 | 31,050 KRW | 25,062 KRW | -19% |
| DongKook Pharmaceutical Co 086450 | 18,350 KRW | 32,142 KRW | +75% |
| Kolon Life Science Inc 102940 | 30,100 KRW | 37,195 KRW | +24% |
| Huons Global Co 084110 | 23,800 KRW | 58,482 KRW | +146% |
| BINEX Co 053030 | 6,350 KRW | 1,844 KRW | -71% |
| Anterogen.Co.,Ltd., a bio-venture company, 065660 | 16,810 KRW | 4,741 KRW | -72% |
| EURO EURO | 1.09 PHP | 0.8700 PHP | -20% |
Compare Daebongls.Co.,Ltd. with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Daebongls.Co.,Ltd. (078140) overvalued or undervalued?
What is the fair value of 078140?
What is the quality score of 078140?
What is the revenue of Daebongls.Co.,Ltd. (078140)?
What is the net profit margin of 078140?
Does Daebongls.Co.,Ltd. pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Daebongls.Co.,Ltd. and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.